沙美特罗/氟替卡松联合噻托溴铵治疗中重度慢性阻塞性肺疾病的临床疗效研究

目的：研究沙美特罗/氟替卡松联合噻托溴铵治疗中重度慢性阻塞性肺疾病（COPD）的临床疗效。方法：68例中重度COPD患者随机分为对照组和治疗组，各34例，对照组给予沙美特罗/氟替卡松，治疗组在给予沙美特罗/氟替卡松的同时吸入噻托溴铵。比较两组治疗前后肺功能指标、呼吸困难评分和6min步行距离（6MWD）。结果：治疗12周后，治疗组肺功能指标（FEV1、FEV1/预计值、FVC和FEV1/FVC）显著改善，与对照组相比，差异均具有统计学意义（P＜0.05）。此外，治疗组治疗12周后呼吸困难评分显著下降，6MWD显著提高，与对照组相比，差异均具有统计学意义（P＜0.05）。结论：沙美特罗/氟替卡松联合噻托溴铵治疗中重度COPD临床疗效显著，优于单独使用沙美特罗/氟替卡松。

The Clinical Effect of Salmeterol/fluticasone Propionate Combined with Tiotropium Bromide for the Treatment in Chronic Obstructive Pulmonary Disease

Objective: To study the clinical effect of salmeterol/fluticasone propionate combined with tiotropium bromide for the treatment in chronic obstructive pulmonary disease (COPD). Methods: Sixty-eight cases of moderate-to-severe COPD patients were randomly divided into control group and treatment group with 34 cases in each group. Control group was given salmeterol/fluticasone , and treatment group was given salmeterol/fluticasone propionate combined with tiotropium bromide. Pulmonary function, dyspnea score and 6-minute walk distance (6MWD) were conducted before and after treatment. Results:After treatment for 12 weeks, pulmonary function of treatment group (FEV1, FEV1/predicted value, FVC and FEV1/FVC) was greatly improved, and significantly superior to that of control group(P<0.05). Also, dyspnea score of treatment group was greatly declined and 6MWD was remarkably improved, and both of them are significantly superior to those of control group (P<0.05). Conclusions:Salmeterol/fluticasone propionate combined with tiotropium bromide could further increase the clinical efficacy than salmeterol/fluticasone propionate in the treatment of moderate-severe COPD.